DECISION related activities at EASL Congress 2024
DECISION strives to better understand the pathophysiology of decompensated cirrhosis leading to acute-on-chronic liver failure (ACLF) at the systems level by taking advantage of already existing large and clinically well-characterized patient cohorts.…
Hepatitis B Is Globally Underassessed and Undertreated, Especially Among Women and Asian Minorities in the West
Amsterdam, May 2, 2024 – New evidence reveals global underassessment and undertreatment of chronic hepatitis B (HBV), especially among women and Asian minorities in the West, a new study in the Journal of…
Tribute to Dr. Stephen Harrison (1969-2024)
The liver community mourns the loss of Dr. Stephen Harrison, a visionary in MASLD clinics and clinical research, whose contributions have shaped the current state of the field. Dr. Stephen Harrison was…
EASL calls on the EU to accelerate public health policies to reduce the high human and financial burden of liver diseases
EASL is the largest professional body in Europe devoted to liver health. EASL’s overarching goal is to spread knowledge and expertise in best practices and the latest scientific breakthroughs in the field…
World Liver Day 2024 – 19 April
World Liver Day, 19 April 2024 Join us in this important, international campaign
GRIPonMASH received significant EU funding to improve prevention and care of Metabolic dysfunction-Associated SteatoHepatitis (MASH)
New European project aims to improve tools and advice to prevent chronic liver illnesses. Utrecht, The Netherlands, 05-02-2024: GRIPonMASH, a newly founded consortium consisting of 27 European institutions and companies, has bundled…
EASL Statement on Resmetirom FDA approval
After over 20 years of dedicated research and drug development, the FDA has granted approval for the first anti-MASH drug. This marks a pivotal moment for patients battling MASH, whose quality of…